FDA Clears Remedy for Excessive Armpit Sweating

By the Editors

The FDA has cleared glycopyrronium (marketed as Qbrexza) to treat primary axillary hyperhidrosis, also known as excessive underarm sweating, the manufacturer announced.

The cloth is approved for use in patients aged 9 years and older and works by inhibiting activation of sweat glands. Common side effects of the anticholinergic include dry mouth, mydriasis, oropharyngeal pain, headache, blurred vision, pruritus, erythema, and dryness of the eye, throat, skin, and nose. It should not be coadministered with other anticholinergic drugs.

The manufacturer anticipates it being on the market in October.